Answers are grounded in this paper and cite their sources.
Sleep disturbances post-COVID-19 are increasingly recognized as one of the most common symptoms. While insomnia is the most frequently reported sleep disorder post-COVID-19, excessive sleep duration and central hypersomnias have also emerged as significant post-acute sequelae. Here, we present a clinical series of ten patients exhibiting sleep disturbances after COVID-19 infection or vaccination. Group A consists of seven adolescents who developed prolonged sleep duration (exceeding their baseline by at least 2 hours) following a COVID-19 infection. Group B includes three cases: one patient with exacerbated delayed sleep–wake phase disorder (DSWPD) post-infection, and two patients who developed central hypersomnias (idiopathic hypersomnia and Narcolepsy Type 1) subsequent to COVID-19 vaccination. For the seven patients with post-infectious prolonged sleep in Group A and for the DSWPD patient in Group B, pharmacological intervention with low-dose aripiprazole (mean final dose 1.4 mg) yielded robust clinical improvements. Recognizing these hypersomnia phenotypes and utilizing targeted therapies like low-dose aripiprazole is critical for restoring daily functioning and providing sustained support for individuals afflicted with Long COVID.
No takes yet. Share an insight, caveat, or question.
Sudo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: